Mario D. Saltarelli Net Worth

The estimated Net Worth of Mario D. Saltarelli is at least $586 Tausend dollars as of 18 May 2015. Mario Saltarelli owns over 4,580 units of Mallinckrodt Plc stock worth over $2,315 and over the last 11 years Mario sold MNK stock worth over $583,675.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mario Saltarelli MNK stock SEC Form 4 insiders trading

Mario has made over 1 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mario sold 4,580 units of MNK stock worth $583,675 on 18 May 2015.

The largest trade Mario's ever made was selling 4,580 units of Mallinckrodt Plc stock on 18 May 2015 worth over $583,675. On average, Mario trades about 1,527 units every 0 days since 2014. As of 18 May 2015 Mario still owns at least 6,808 units of Mallinckrodt Plc stock.

You can see the complete history of Mario Saltarelli stock trades at the bottom of the page.

What's Mario Saltarelli's mailing address?

Mario's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.

Insiders trading at Mallinckrodt Plc

Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... und Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.

What does Mallinckrodt Plc do?

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit

Complete history of Mario Saltarelli stock trades at Mallinckrodt Plc

Mallinckrodt Plc executives and stock owners

Mallinckrodt Plc executives and other stock owners filed with the SEC include:

• Mark Trudeau,
  President, Chief Executive Officer, Director
• Steven Romano,
  Executive Vice President, Chief Scientific Officer
• Hugh O'Neill,
  Executive Vice President, Chief Commercial Officer
• Mark Casey,
  Executive Vice President and Chief Legal Officer
• Bryan Reasons,
  Chief Financial Officer, Executive Vice President
• Ian Watkins,
  Chief Human Resource Officer, Executive Vice President
• Angus Russell,
  Independent Non-Executive Chairman of the Board
• JoAnn Reed,
  Independent Director
• J. Martin Carroll,
  Independent Director
• David Norton,
  Independent Director
• Kneeland Youngblood,
  Independent Director
• Anne Whitaker,
  Independent Director
• Paul Carter,
  Independent Director
• Carlos Paya,
  Independent Director
• Daniel Speciale,
  Vice President - Investor Relations and IRO
• David R Carlucci,
  Director
• Virgil D Thompson,
  Director
• Diane H. Gulyas,
  Director
• Matthew K Harbaugh,
  SVP&Chief Financial Officer
• Michael Bryant Hicks,
  Sr. VP & General Counsel
• Ronald K. Lloyd,
  Sr. VP & Pres, Hospital
• Raymond J. Furey,
  SVP & Chief Compliance Officer
• Gary M. Phillips,
  Sr. VP & Chief Strategy Ofcr.
• Meredith B Fischer,
  SVP, Communic. & Public Affair
• Melvin D Booth,
  Director
• Joseph A Zaccagnino,
  Director
• Coleman N Iii Lannum,
  VP, Investor Relations
• Dagmar Rosa Bjorkeson,
  Chief Strat & Corp Dev Officer
• Sigurdur O Olafsson,
  President and CEO
• Kassie Harrold,
  Chief Compliance Officer
• Jason Daniel Goodson,
  EVP & Head of Corp Development
• Henriette Nielsen,
  EVP & Chief Transformation OFC
• Lisa French,
  EVP & Chief Commercial Officer
• Mark Anthony Tyndall,
  EVP & Chief Legal Offi & Secre
• Stephen Andrew Welch,
  EVP & Head of Spec Generics
• Frank Scholz,
  SVP, Global Operations
• George A. Kegler,
  EVP & CFO, Interim
• Karen Patruno Sheehy,
  Sr. VP & Chief Compliance Off.
• James E Deerfield Mgmt L.P....,
  
• Don M Bailey,
  Director
• Sandra L Hatten,
  Sr. Vice President Quality
• Terrance L Carlson,
  Interim General Counsel
• & Co. Inc. Paulson,
  10% owner
• Holding Ltd Enceladus,
  
• Thomas E Berry,
  See Remarks
• Peter G Edwards,
  See Remarks
• Stefano R Carchedi,
  See Remarks
• Stephen Merrick,
  See Remarks
• Nancy Lurker,
  Director
• Mario D. Saltarelli,
  Sr. VP & Chief Science Ofcr.
• Kathy A Schaefer,
  Sr. VP Fin & Corp. Controller
• Peter C Richardson,
  EVP & Chief Scientific Officer
• Daniel Arthur Celentano,
  Director
• Woodrow A Jr Myers,
  Director
• Paul Bisaro,
  Director
• James R Sulat,
  Director
• Susan Michele Silbermann,
  Director
• Karen Ling,
  Director
• Neal P Goldman,
  Director
• Riad Hussein El Dada,
  Director